|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||5.45 - 6.01|
|52 Week Range||5.43 - 29.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2018 - Aug 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.75|
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that its scientific founder, Dr. James P. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine for the discovery of cancer therapy by inhibition of negative immune regulation. Since our founding, Jounce has benefited tremendously from his leadership, expertise and dedication to cancer immunotherapy and this award is a testament to all that he has accomplished,” said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. “Jim played a fundamental role in ushering in the era of cancer immunotherapy, including his contributions to the understanding of the basic science of CTLA-4.
CAMBRIDGE, Mass., Sept. 26, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
CAMBRIDGE, Mass., Aug. 29, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alamos ...
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
-Initiated enrollment in dose escalation cohorts of Phase 1/ 2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab-. -Presented preliminary efficacy data for ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Jounce Therapeutics, Inc. (NASDAQ: JNCE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern ...
CAMBRIDGE, Mass., Aug. 02, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own ...
In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took a significant haircut, but was the drop justified? The goal of the therapy is to tip the balance between these two subtypes of T-cells towards the effector cells by depleting T-regs through antibody activity (ADCC) and encouraging growth of T-effector cells which express ICOS.
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Both Loxo Oncology and Jounce Therapeutics shares went in different directions after traders absorbed abstract reveals from each company. Shares of Loxo soared ...
Wells Fargo Securities analyst Jim Birchenough downgraded Jounce from Outperform to Market Perform and lowered the price target from $37 to $13. The overall response rate for JTX-2011 as a monotherapy in gastric cancer and triple negative breast cancer, and for the JTX-2011-Opdivo combo in gastric cancer and TNBC, is underwhelming, Birchenough said in a Thursday note.